Literature DB >> 23122666

Soluble epoxide hydrolase disruption as therapeutic target for wound healing.

Anna L Sander1, Katharina Sommer, Thomas Neumayer, Ingrid Fleming, Ingo Marzi, John H Barker, Johannes Frank, Heike Jakob.   

Abstract

BACKGROUND: Cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) possess angiogenic effects. However, the effect of CYP-derived EETs and soluble epoxide hydrolase (sEH) deletion on wound healing in vivo has not been rigorously investigated. In this study, we measured the effect of exogenous CYP-derived EETs and targeted disruption of sEH in an in vivo wound model.
MATERIALS AND METHODS: Standardized full-thickness dermal wounds were created on the dorsum of mouse ears. Wound epithelialization was directly viewed and measured using intravital microscopy and computerized planimetry every second day until healing was complete. Wound sections were analyzed by immunostaining for metalloproteinase (MMP) 2, MMP7, MMP9, tissue inhibitor of metalloproteinases (TIMP) 1, and tumor necrosis factor (TNF) α on days 2, 4, and 12.
RESULTS: Treatment with 11,12-EETs, 14,15-EETs, and sEH deletion significantly accelerated wound closure. This effect was attenuated by the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) in sEH(-/-) mice. Neither 11,12- nor 14,15-EETs caused significant alterations in MMP9 expression in wounds. In contrast, MMP2 and MMP7 were significantly upregulated in the EET-treated groups, whereas TIMP1 and TNF-α were downregulated.
CONCLUSIONS: Collectively, these data demonstrated that potentiation of the CYP epoxy-genase pathway by either exogenous CYP-derived EETs or sEH deletion significantly accelerated wound epithelialization in vivo. This beneficial effect might be due to downregulation of TNF-α production and, to a lesser degree, to the release of MMPs and could be used as a viable angiogenic therapeutic strategy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23122666     DOI: 10.1016/j.jss.2012.10.034

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  16 in total

1.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

2.  Cytochrome P450 (CYP) epoxygenases as potential targets in the management of impaired diabetic wound healing.

Authors:  Huichen Zhao; Jicui Chen; Jiachao Chai; Yuchao Zhang; Cong Yu; Zhe Pan; Peng Gao; Chen Zong; Qingbo Guan; Yuqin Fu; Yuantao Liu
Journal:  Lab Invest       Date:  2017-03-20       Impact factor: 5.662

3.  Proinflammatory enzyme soluble epoxide hydrolase bridges obesity to colonic inflammation and potential carcinogenesis.

Authors:  Guang-Yu Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-16       Impact factor: 11.205

4.  Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction.

Authors:  Yann Savina; Thomas Duflot; Frederic Bounoure; Sylvain Kotzki; Pierre-Alain Thiebaut; Pierre-Alex Serreau; Mohamed Skiba; Jean-Michel Picquenot; Marie Cornic; Christophe Morisseau; Bruce Hammock; Laurent Imbert; Jean-Luc Cracowski; Vincent Richard; Matthieu Roustit; Jeremy Bellien
Journal:  Diab Vasc Dis Res       Date:  2019-07-03       Impact factor: 3.291

5.  Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.

Authors:  Sung Hee Hwang; Aaron T Wecksler; Guodong Zhang; Christophe Morisseau; Long V Nguyen; Samuel H Fu; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2013-05-15       Impact factor: 2.823

6.  Genetic deletion of soluble epoxide hydrolase attenuates inflammation and fibrosis in experimental obstructive nephropathy.

Authors:  Chin-Wei Chiang; Hsueh-Te Lee; Der-Cherng Tarng; Ko-Lin Kuo; Li-Ching Cheng; Tzong-Shyuan Lee
Journal:  Mediators Inflamm       Date:  2015-01-22       Impact factor: 4.711

7.  Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.

Authors:  Yan Gong; Zhuo Shao; Zhongjie Fu; Matthew L Edin; Ye Sun; Raffael G Liegl; Zhongxiao Wang; Chi-Hsiu Liu; Samuel B Burnim; Steven S Meng; Fred B Lih; John Paul SanGiovanni; Darryl C Zeldin; Ann Hellström; Lois E H Smith
Journal:  EBioMedicine       Date:  2016-09-30       Impact factor: 8.143

8.  Epoxyeicosanoids prevent intervertebral disc degeneration in vitro and in vivo.

Authors:  Jing Li; Hanfeng Guan; Huiyong Liu; Libo Zhao; Li Li; Yong Zhang; Peng Tan; Baoguo Mi; Feng Li
Journal:  Oncotarget       Date:  2017-01-17

9.  Soluble Epoxide Hydrolase Inhibition and Epoxyeicosatrienoic Acid Treatment Improve Vascularization of Engineered Skin Substitutes.

Authors:  Dorothy M Supp; Jennifer M Hahn; Kevin L McFarland; Kelly A Combs; Kin Sing Stephen Lee; Bora Inceoglu; Debin Wan; Steven T Boyce; Bruce D Hammock
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-12-20

Review 10.  Wound Healing and Omega-6 Fatty Acids: From Inflammation to Repair.

Authors:  Jéssica R Silva; Beatriz Burger; Carolina M C Kühl; Thamiris Candreva; Mariah B P Dos Anjos; Hosana G Rodrigues
Journal:  Mediators Inflamm       Date:  2018-04-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.